Endometrial cancer medical therapy: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Monalisa Dmello (talk | contribs)
CMEUser, nocaptcha
4,359 edits
No edit summary
Monalisa Dmello (talk | contribs)
CMEUser, nocaptcha
4,359 edits
No edit summary
Line 10: Line 10:
:* Patients with stage III endometrial cancer are treated with [[surgery]], followed by [[chemotherapy]], or [[radiation therapy]], or both.
:* Patients with stage III endometrial cancer are treated with [[surgery]], followed by [[chemotherapy]], or [[radiation therapy]], or both.
:* Patients with inoperable disease caused by tumor that extends to the pelvic wall may be treated with a combination of chemotherapy and radiation therapy. The usual approach is to use a combination of intracavitary radiation therapy and external-beam radiation therapy.
:* Patients with inoperable disease caused by tumor that extends to the pelvic wall may be treated with a combination of chemotherapy and radiation therapy. The usual approach is to use a combination of intracavitary radiation therapy and external-beam radiation therapy.
*Clinical trials
::*1. In a trial conducted in a subset of patients with stage III or IV disease with residual tumors smaller than 2 cm and no parenchymal organ involvement, the use of the combination of [[Cisplatin]] and [[Doxorubicin]] resulted in improved overall survival (OS) compared with whole-abdominal radiation therapy (adjusted hazard ratio, 0.68; 95% confidence interval limits, 0.52–0.89;P = .02; 5-year survival rates of 55% vs. 42%).[Level of evidence: 1iiA]
::* 2.The three-drug regimen ([[Doxorubicin]], [[Cisplatin]], and [[Paclitaxel]]) with granulocyte colony-stimulating factor (G-CSF), was significantly superior to [[Cisplatin]] plus [[Doxorubicin]]: response rates were 57% versus 34%; progression-free survival was 8.3 months versus 5.3 months; and overall survival (OS) was 15.3 months versus 12.3 months.


'''Stage IV endometrial cancer'''
'''Stage IV endometrial cancer'''
:* Treatment of patients with stage IV endometrial cancer is dictated by the site of metastatic disease and symptoms related to disease sites. For bulky pelvic disease, radiation therapy consisting of a combination of intracavitary and external-beam radiation therapy is used.
:* Treatment of patients with stage IV endometrial cancer is dictated by the site of metastatic disease and symptoms related to disease sites. For bulky pelvic disease, radiation therapy consisting of a combination of intracavitary and external-beam radiation therapy is used.
* Clinical Trials
:* several randomized trials have confirmed improved survival when adjuvant chemotherapy is used instead of radiation therapy.
::* 1.  In a trial conducted in a subset of patients with stage III or IV disease with residual tumors smaller than 2 cm and no parenchymal organ involvement, the use of the combination of [[Cisplatin]] and doxorubicin resulted in improved overall survival (OS) compared with whole-abdominal radiation therapy (adjusted hazard ratio, 0.68; 95% confidence interval limits, 0.52–0.89;P = .02; 5-year survival rates of 55% vs. 42%).[Level of evidence: 1iiA]
::* 2.The three-drug regimen ([[Doxorubicin]], [[Cisplatin]], and [[Paclitaxel]]) with granulocyte colony-stimulating factor (G-CSF), was significantly superior to [[Cisplatin]] plus [[Doxorubicin]]: response rates were 57% versus 34%; progression-free survival was 8.3 months versus 5.3 months; and overall survival (OS) was 15.3 months versus 12.3 months.
::* 3. The most common hormonal treatment has been progestational agents, which produce good antitumor responses in as many as 15% to 30% of patients. These responses are associated with significant improvement in survival. Progesterone and estrogen hormone receptors have been identified in endometrial carcinoma tissues. Responses to hormones are correlated with the presence and level of hormone receptors and the degree of tumor differentiation. Standard progestational agents include [[Hydroxyprogesterone]], [[Medroxyprogesterone]], and [[Megestrol]].
::* 4. Biologic agents under evaluation for patients with advanced and recurrent endometrial cancer include,[[Bevacizumab]] and [[Temsirolimus]].


==References==
==References==

Revision as of 20:20, 4 September 2015

Endometrial cancer Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Endometrial cancer from other Diseases

Epidemiology and Demographics

Risk factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Endometrial cancer medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Endometrial cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endometrial cancer medical therapy

CDC on Endometrial cancer medical therapy

Endometrial cancer medical therapy in the news

Blogs on Endometrial cancer medical therapy

Directions to Hospitals Treating Endometrial cancer

Risk calculators and risk factors for Endometrial cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The optimal therapy for endometrial cancer depends on the stage at diagnosis.

Medical Therapy

Stage III endometrial cancer

  • Patients with stage III endometrial cancer are treated with surgery, followed by chemotherapy, or radiation therapy, or both.
  • Patients with inoperable disease caused by tumor that extends to the pelvic wall may be treated with a combination of chemotherapy and radiation therapy. The usual approach is to use a combination of intracavitary radiation therapy and external-beam radiation therapy.

Stage IV endometrial cancer

  • Treatment of patients with stage IV endometrial cancer is dictated by the site of metastatic disease and symptoms related to disease sites. For bulky pelvic disease, radiation therapy consisting of a combination of intracavitary and external-beam radiation therapy is used.

References


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Endometrial_cancer_medical_therapy&oldid=1152532"